LucidScope
AI is already answering questions about your brand. LucidScope shows you what it’s saying, and why.
LucidScope evaluates how leading AI systems respond to real-world questions about your company, products, indications, and competitors.
It maps visibility and positioning in AI-generated answers, traces the sources shaping those answers, and highlights gaps where evidence is missing, outdated, or misrepresented.
What you can do with LucidScope:
-
Perception Mapping: Compare how AI positions your brand versus key competitors.
- See how AI frames your brand versus competitors, by theme and attribute.
-
Answers Mapping: See how models answer the same stakeholder questions, and where they diverge.
- View side-by-side model answers to your key questions, with differences highlighted.
-
Source Tracing: Identify which websites and documents are shaping AI answers, and where to intervene.
- Understand which domains and documents drive the answers, and what’s missing.
-
Launch and campaign monitoring: Track changes over time across models, markets, and topics.
- Monitor shifts in positioning, key claims, and cited sources (you vs competitors).
Want to see what AI is saying about your brand? Request an AI Answer Audit.
You’ll receive a short report covering Perception, Answers, Source Tracing, and Zero-click gaps.
Already evaluating tools? Test LucidScope.
Questions or feedback? Email us anytime.
January 9, 2026
Vaccines Today—January 9, 2026
January 9, 2026
Respiratory Video Recap—January 9, 2026
January 9, 2026
Respiratory Today—January 9, 2026
January 9, 2026
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
January 8, 2026
Cardiovascular Today—January 8, 2026
January 8, 2026
Rare Disease Today—January 8, 2026
January 8, 2026
Immunology Today—January 8, 2026
January 8, 2026
Cell and Gene Therapy Video Recap—January 8, 2026
January 8, 2026
Cell and Gene Therapy Today—January 8, 2026
January 8, 2026
AI in Healthcare and Digital Health Today—January 8, 2026
January 8, 2026
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
January 7, 2026